Neoadjuvant Cabozantinib in Renal-Cell Carcinoma: A Brief Review

Roy, Arya Mariam; Briggler, Andrew M.; Tippit, Danielle; Dawson, Kellen; Verma, Rashmi

doi:10.1016/j.clgc.2020.04.003

Cited by 12 publications

(4 citation statements)

References 20 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In several phase 2 trials addressing the neoadjuvant strategy low complete response rate has been typically observed (10-12). Neoadjuvant cabozantinib in patients with unresectable locally advanced RCC facilitating nephrectomy has also been reported (13)(14)(15). Combination therapy of nivolumab and cabozantinib yielded the greatest reduction in the primary tumor size in a retrospective study (16).…”

Section: Discussionmentioning

confidence: 94%

Neoadjuvant nivolumab and cabozantinib in advanced renal cell carcinoma in a horseshoe kidney – how to achieve a safe and radical resection? a case report and review of the literature

Zemankova,

Studentova,

Kopova

et al. 2023

Front. Oncol.

View full text Add to dashboard Cite

IntroductionNeoadjuvant nivolumab and cabozantinib in locally advanced renal cell carcinoma in a horseshoe kidney is a novel therapeutic approach in the preoperative setting.MethodsWe report a case of a 52-year old male who presented with a large inoperable tumor of the horseshoe kidney and achieved major partial radiologic response after neoadjuvant therapy with nivolumab and cabozantinib leading to radical resection of the tumor. The patient remains tumor free on the subsequent follow-up and his renal function is only mildly decreased. The systemic treatment was complicated by hepatotoxicity leading to early nivolumab withdrawal.ResultsCurrently, the combination therapy based on immune checkpoint inhibitors and tyrosine kinase inhibitors represents the treatment of choice in treatment-naïve patients with metastatic renal cell carcinoma in any prognostic group. The neoadjuvant treatment approach is being tested in prospective clinical trials and results are eagerly awaited. Renal cell carcinoma in a horseshoe kidney is an uncommon finding that is always challenging. Additionally, management guidance in this patient population is lacking. In some patients neoadjuvant therapy could be the only way to preserve kidney function. The initial treatment strategy should be individualized to patient needs aiming at the radical resection of the primary tumor as the only chance of getting the tumor under control in the long term.ConclusionHerein, we highlight the feasibility of neoadjuvant systemic therapy with nivolumab and cabozantinib allowing the subsequent performance of radical tumor resection with negative margins in a patient with advanced renal cell carcinoma in a horseshoe kidney, removing the primary tumor while sparing the patient from lifelong dialysis.

show abstract

Section: Discussionmentioning

confidence: 94%

Neoadjuvant nivolumab and cabozantinib in advanced renal cell carcinoma in a horseshoe kidney – how to achieve a safe and radical resection? a case report and review of the literature

Zemankova,

Studentova,

Kopova

et al. 2023

Front. Oncol.

View full text Add to dashboard Cite

show abstract

“…Phase 2 studies and case series addressing this treatment approach with the aim of downstaging the primary tumor using multiple tyrosine kinase inhibitors (MTKIs) have been reported, but results have shown low complete response rates [ 9 ]. The preoperative strategy aiming to widen the surgical options resulting in a curative approach was not successful with MTKIs except of occasional case reports [ 10 , 11 , 12 ]. Recently, Gorin et al published data on 17 high-risk nonmetastatic RCC patients treated with preoperative nivolumab (only 3 doses of nivolumab, 240 mg, administered intravenously) with 1 patient experiencing pathological response with immune-related features in the removed kidney [ 13 ].…”

Section: Discussionmentioning

confidence: 99%

A Pathological Complete Response to the Combination of Ipilimumab and Nivolumab in a Patient with Metastatic Renal Cell Carcinoma

et al. 2022

View full text Add to dashboard Cite

Background and Objectives: Complete pathological response after ipilimumab and nivolumab combination therapy in a patient with intermediate prognosis renal cell carcinoma is an uncommon finding. Case presentation: A 60-year-old man presented with synchronous solitary metastatic bone lesion and renal cell carcinoma and achieved a complete pathological response after surgical resection of the bone lesion, followed by ipilimumab and nivolumab combination therapy and nephrectomy. The treatment was complicated by hypophysitis and oligoarthritis more than a year after the initiation of the therapy. Conclusions: Currently, the combination therapy based on immune checkpoint inhibitors represents the treatment of choice in patients with intermediate- and poor-risk prognosis metastatic renal cell carcinoma. In the present case, preoperative therapy with ipilimumab and nivolumab resulted in a complete pathological response in the renal tumor. Vigilance concerning potential immune-related side effects is warranted throughout the course of therapy and the subsequent follow-up.

show abstract

“…Effective adjuvant therapies are necessary to reduce recurrence andmetastasis, such as autologous tumor vaccines, carbonic anhydrase IX monoclonal antibody, tyrosine kinase inhibitors and novel immunotherapies, which have significantly improved the overall survival of patients with RCC in recent years[ 14 , 24 , 25 ]. To date, most studies have focused on the identification of an effective adjuvant therapy for CCRCC, in order to improve the outcome of patients with high-risk RCC, while the optimal treatment option for PRCC has not yet been established[ 26 ].…”

Section: Discussionmentioning

confidence: 99%

Ipsilateral synchronous papillary and clear renal cell carcinoma: A case report and review of literature

Yin¹

2022

WJCC

View full text Add to dashboard Cite

BACKGROUND There is limited information on ipsilateral synchronous papillary renal cell carcinoma (PRCC) and clear cell renal cell carcinoma (CCRCC). Therefore, these rare tumors are often misdiagnosed preoperatively as a single tumor with intrarenal metastasis or some other diseases. Effective management and long-term overall survival might be affected because the prognosis of the two tumors differs. CASE SUMMARY We describe a case of ipsilateral synchronous PRCC and CCRCC with two histological variants in a 72-year-old man, whose mass was found incidentally, with no other chief complaints and vital signs were normal. Initial ultrasound revealed a hypoechoic lobular mass with a volume of 7.8 cm × 4.8 cm × 2.8 cm in the middle to lower pole of the left kidney. A subsequent contrast-enhanced computed tomography scan showed a single endophytic mass of 7.5 cm in diameter. The patient underwent laparoscopic left radical nephrectomy. A final diagnosis of ipsilateral synchronous PRCC and CCRCC was confirmed by pathological examination. There was no recurrence or metastasis after 25 mo follow-up. CONCLUSION We report a case of ipsilateral synchronous PRCC and CCRCC, and review related literature to estimate the prevalence of similar cases. The above descriptions may be expected to help understand the disease, and improve diagnosis in the future.

show abstract

Neoadjuvant Cabozantinib in Renal-Cell Carcinoma: A Brief Review

Cited by 12 publications

References 20 publications

Neoadjuvant nivolumab and cabozantinib in advanced renal cell carcinoma in a horseshoe kidney – how to achieve a safe and radical resection? a case report and review of the literature

Neoadjuvant nivolumab and cabozantinib in advanced renal cell carcinoma in a horseshoe kidney – how to achieve a safe and radical resection? a case report and review of the literature

A Pathological Complete Response to the Combination of Ipilimumab and Nivolumab in a Patient with Metastatic Renal Cell Carcinoma

Ipsilateral synchronous papillary and clear renal cell carcinoma: A case report and review of literature

Contact Info

Product

Resources

About